The cut-off point, 500 U/mL, used by Obeidat Basil, et al. was obtained from Chi’s study with stage III ovarian cancer patients as the samples [22], yielding a sensitivity of 72% and specificity of 73% for predicting suboptimal cytoreduction surgery by CA-125 [19]. Here, MUC16 is linked to ovarian cancer.